In March of 2017, Immune Therapeutics, Inc. announced that it signed a Memorandum of Understanding (“MOU”) for distribution of its patented Lodonal™ in Kenya.
The Company plans to reach commercialization for Lodonal in Kenya in 2017. It is following the same strategy in Nigeria, where the process is further ahead, having already received the COPP, and is anticipated to reach commercialization by mid-2017.
For more information regarding this project contact Investor Relations Counsel:
Investor Relations Partners